← 產業報告目錄

Compounding Pharmacy Market by Product (Oral, Topical, Parenteral), Compounding Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT), Sterility (Sterile), End User (Pediatric, Adult) - Global forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-10-20頁數 305報告編號 PH9569

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global compounding pharmacy market is projected to reach USD 19.41 billion by 2030 from an estimated USD 14.72 billion in 2025, at a CAGR of 5.7% from 2025 to 2030. The market's growth has mainly been driven by the increasing trend toward personalized doses. However, capacity constraints in API, excipient supply, and CCI/testing are expected to limit the market. The oral drugs held the highest share in the compounding pharmacy market by product type. The compounding pharmacy market is segmented by product type into topical drugs, oral drugs, parenteral drugs, rectal drugs, nasal drugs, ophthalmic drugs, and other products. Among these, the oral drugs segment holds a key position in the global market, driven by the increasing need for personalized therapies tailored to individual patient requirements. This segment includes a wide variety of formulations such as capsules, tablets, lozenges, solutions, and suspensions, which are extensively used in hormone replacement therapy, pediatric and geriatric care, pain management, gastrointestinal treatments, and chronic disease management. Compounded oral medications enable pharmacists to customize dosage strengths, flavors, excipients, and release profiles, thereby improving patient compliance—especially among those who have difficulty swallowing standard tablets or who need precise dosing. The rising prevalence of chronic conditions like cardiovascular diseases, diabetes, and endocrine disorders further fuels this segment’s growth by creating demand for personalized oral treatments that maximize efficacy and reduce side effects. Technological innovations, including sustained-release systems, taste-masking techniques, and bioavailability-enhancing carriers, improve therapeutic performance and patient experience. Adherence to FDA regulations and USP standards ensures safety, sterility, and quality, building confidence among healthcare providers and patients. Along with the growing emphasis on personalized medicine and increased availability through hospitals, specialty clinics, and retail pharmacies, oral drugs continue to be a major driver of revenue growth. The segment’s focus on convenience, customization, and effective therapy highlights its vital role in the overall development of the global compounding pharmacy market. The pain management segment reported the highest share of the therapeutic application segment in 2024 The pain management segment holds the largest share in the pharmaceutical market by therapeutic application, driven by the global prevalence of acute and chronic pain conditions across musculoskeletal, neuropathic, and post-surgical patient groups. Increasing cases of arthritis, back pain, cancer-related pain, and migraines have boosted demand for effective pain relief therapies, including NSAIDs, opioids, topical analgesics, and combination treatments. The rising use of personalized pain management options, such as sustained-release formulations and targeted delivery systems, improves effectiveness while reducing systemic side effects, further increasing patient adherence and market growth. Technological advances, like transdermal patches and localized injectable therapies, have broadened treatment choices and made long-term pain management more convenient for patients. Favorable insurance coverage, greater awareness of pain as a key health issue, and the expanding elderly population support consistent growth in this segment. Leading pharmaceutical firms are enhancing their portfolios through research into new analgesics, biologics, and non-opioid alternatives, positioning themselves to capture larger market shares. As the need for safe, effective, and patient-focused pain management solutions continues to grow, this therapeutic segment is expected to stay dominant, reflecting sustained revenue increases and ongoing innovation in both developed and emerging markets. North America accounted for the largest market share in the global Compounding pharmacy market from 2025 to 2030. North America remains the leading region in the global compounding pharmacy market, mainly due to the United States. The region's dominance is linked to its strong healthcare infrastructure, strict regulatory standards, and a large presence of both 503A and 503B compounding pharmacies. These pharmacies are essential in providing personalized medications, especially where commercially available drugs are insufficient. The US market offers a wide variety of compounded products, including oral, topical, and sterile preparations, to meet different therapeutic needs. Recent trends show a rising demand for specialized compounded medications, particularly in pain management, hormone replacement therapy, and pediatric care. Regulatory agencies like the FDA continue to monitor and ensure the safety and effectiveness of compounded drugs, building trust within the healthcare system. This combination of factors highlights North America's key role in advancing and improving access to compounding pharmacy services. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side-70% and Demand Side-30% • By Designation: Managers-45%, CXO and Directors-30%, and Executives-25% • By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5% List of Key Companies Profiled in the Report: Key players in the Compounding pharmacy market include Baxter (US), Empower Pharmacy (US), B. Braun (Germany), Fagron (Netherlands), QuVa Pharma (US), SCA Pharma (US), Nephron Pharmaceuticals (US), Leiters Health (US), Pharmaxo (UK), Icon Group (Australia), Roseway Labs (UK), ITH Pharma (UK), Pencol Compounding Pharmacy (Canada), Formula 8 (South Africa), and Aurora Compounding Pharmacy (Canada) Research Coverage: This research report categorizes the compounding pharmacy market by product (oral, topical, parenteral), compounding type (ingredient alteration, dosage alteration), therapeutic application (pain management, HRT), sterility (sterile), and end user (pediatric, adult). The scope of the report includes detailed information about the main factors affecting the growth of the Compounding pharmacy market, such as drivers, restraints, challenges, and opportunities. It also features an in-depth analysis of key industry players, offering insights into their business overview, products, solutions, strategies, collaborations, partnerships, and agreements. The report covers recent developments like new approvals, launches, collaborations, acquisitions, and other updates related to the Compounding pharmacy market. Key Benefits of Buying the Report: The report will assist market leaders and new entrants by providing them with the closest estimates of revenue figures for the entire Compounding pharmacy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop appropriate go-to-market strategies. This report will enable stakeholders to grasp the market's key indicators and offer information on the main market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (Persistent drug shortages in North America and Europe, full enforcement of USP standards, safety push for ready-to-administer and standardized doses, continued demand creating supply gap for GLP-1 drugs, and trend toward personalization of doses), restraints (Resolution of GLP-1 shortages reduces reliance on compounded alternatives, stricter FDA oversight and insanitary conditions enforcement, and limitations on bulk drug substances.), opportunities (Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic & chemo-adjuncts and Radiopharmaceutical compounding standardization), and challenges (Capacity bottlenecks in API, excipient supply, and CCI/testing, and limited quality-system maturity and gaps in stability/BUD evidence generation.) influencing the growth of the market. • Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the compounding pharmacy market • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions. • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the compounding pharmacy market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the Compounding pharmacy market.
目錄 Table of Contents
1 INTRODUCTION 31 1.1 STUDY OBJECTIVES 31 1.2 MARKET DEFINITION 31 1.3 STUDY SCOPE 32 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 32 1.3.2 INCLUSIONS & EXCLUSIONS 33 1.3.3 YEARS CONSIDERED 33 1.3.4 CURRENCY CONSIDERED 34 1.4 STAKEHOLDERS 34 2 RESEARCH METHODOLOGY 35 2.1 RESEARCH DATA 35 2.1.1 SECONDARY DATA 36 2.1.1.1 Objectives of secondary research 36 2.1.1.2 Key data from secondary sources 37 2.1.2 PRIMARY DATA 37 2.1.2.1 Breakdown of primaries (supply- and demand-side participants) 38 2.1.2.2 Key objectives of primary research 38 2.2 MARKET SIZE ESTIMATION 39 2.2.1 GLOBAL MARKET ESTIMATION 39 2.2.1.1 Company revenue analysis (bottom-up approach) 39 2.2.1.2 Revenue share analysis 40 2.2.1.3 MnM repository analysis 41 2.2.1.4 Primary interviews 41 2.2.2 INSIGHTS OF PRIMARY EXPERTS 41 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 42 2.3 MARKET GROWTH RATE PROJECTIONS 43 2.4 DATA TRIANGULATION 45 2.5 STUDY ASSUMPTIONS 46 2.6 RESEARCH LIMITATIONS 47 2.7 RISK ANALYSIS 47 3 EXECUTIVE SUMMARY 48 3.1 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 48 3.2 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS 49 3.2.1 STARTUPS AND INNOVATIVE COMPANIES 49 3.2.2 ESTABLISHED MARKET LEADERS 49   4 PREMIUM INSIGHTS 54 4.1 COMPOUNDING PHARMACY MARKET OVERVIEW 54 4.2 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT AND COUNTRY (2025) 55 4.3 COMPOUNDING PHARMACY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56 4.4 COMPOUNDING PHARMACY MARKET: EMERGING VS. DEVELOPED MARKETS 57 4.5 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 57 4.6 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 58 4.7 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 58 4.8 REGULATORY POLICY INITIATIVES 59 5 MARKET OVERVIEW 60 5.1 INTRODUCTION 60 5.2 MARKET DYNAMICS 60 5.2.1 DRIVERS 61 5.2.1.1 Persistent drug shortages in North America and Europe 61 5.2.1.2 Enforcement of USP standards 62 5.2.1.3 Push for ready-to-administer (RTA) and standardized doses 62 5.2.1.4 Continued demand-supply gap for GLP-1 drugs 63 5.2.1.5 Trend towards personalization of doses 63 5.2.2 RESTRAINTS 64 5.2.2.1 Resolution of GLP-1 shortages and reduced reliance on compounded alternatives 64 5.2.2.2 Stricter FDA oversight and intensified enforcement of unsanitary conditions violations 64 5.2.2.3 Limitations on bulk drug substances 64 5.2.3 OPPORTUNITIES 65 5.2.3.1 Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic, and chemo-adjuncts 65 5.2.3.2 Radiopharmaceutical compounding standardization 65 5.2.4 CHALLENGES 66 5.2.4.1 Capacity bottlenecks in API, excipient supply, and critical compounding infrastructure testing 66 5.2.4.2 Limited quality-system maturity and gaps in stability/BUD evidence generation 66 5.3 PORTER’S FIVE FORCES ANALYSIS 67 5.3.1 THREAT OF NEW ENTRANTS 68 5.3.2 THREAT OF SUBSTITUTES 68 5.3.3 BARGAINING POWER OF SUPPLIERS 68 5.3.4 BARGAINING POWER OF BUYERS 68 5.3.5 INTENSITY OF COMPETITIVE RIVALRY 69   5.4 KEY STAKEHOLDERS & BUYING CRITERIA 69 5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS 69 5.4.2 KEY BUYING CRITERIA 71 5.5 MACROECONOMICS INDICATORS 72 5.5.1 HEALTHCARE EXPENDITURE TRENDS 72 5.5.2 GLOBAL CANCER BURDEN 73 5.5.3 IMPACT OF PHARMA R&D 74 5.6 VALUE CHAIN ANALYSIS 75 5.7 ECOSYSTEM ANALYSIS 77 5.7.1 ROLE IN ECOSYSTEM 78 5.8 PRICING ANALYSIS 79 5.8.1 INDICATIVE PRICING ANALYSIS OF COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2024 79 5.8.2 INDICATIVE PRICING ANAYLSIS OF COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2024 80 5.9 KEY CONFERENCES & EVENTS, 2025–2026 80 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 81 5.11 INVESTMENT & FUNDING SCENARIO 82 5.12 TECHNOLOGY ANALYSIS 83 5.12.1 KEY TECHNOLOGIES 83 5.12.1.1 Automated compounding devices 83 5.12.1.2 Sterile compounding equipment 83 5.12.2 COMPLEMENTARY TECHNOLOGIES 84 5.12.2.1 Quality control & testing systems 84 5.12.2.2 Pharmacy information management software (PIMS) 84 5.12.3 ADJACENT TECHNOLOGIES 84 5.12.3.1 3D printing of pharmaceuticals 84 5.12.3.2 Personalized medicine platforms 85 5.13 IMPACT OF AI/GEN AI ON COMPOUNDING PHARMACY MARKET 85 5.14 REGULATORY ANALYSIS 86 5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION 86 5.14.2 REGULATORY FRAMEWORK 89 5.15 IMPACT OF 2025 US TARIFF ON COMPOUNDING PHARMACY MARKET 92 5.15.1 INTRODUCTION 92 5.15.2 KEY TARIFF RATES 93 5.15.3 PRICE IMPACT ANALYSIS 94 5.15.4 IMPACT ON COUNTRY/REGION 94 5.15.4.1 US 94 5.15.4.2 Europe 95 5.15.4.3 Asia Pacific 95 5.15.4.4 Rest of the World 96 5.15.5 IMPACT ON MANUFACTURING INDUSTRIES 96 5.16 UNMET NEEDS & WHITE SPACES 97 6 COMPOUNDING PHARMACY MARKET, BY PRODUCT 98 6.1 INTRODUCTION 99 6.2 ORAL DRUGS 99 6.2.1 INCREASING DEMAND FOR PRECISE AND CUSTOMIZABLE ORAL FORMULATIONS IN UNMET PATIENT POPULATIONS TO DRIVE MARKET 99 6.3 TOPICAL DRUGS 102 6.3.1 RISING DEMAND FOR PERSONALIZED TOPICAL TREATMENTS AND ADVANCED DELIVERY VEHICLES TO FUEL MARKET GROWTH 102 6.4 PARENTERAL DRUGS 105 6.4.1 RISING DEMAND FOR STERILE INJECTABLE THERAPIES AND SUPPLY-CHAIN DISRUPTIONS TO BOOST MARKET GROWTH 105 6.5 OPTHALMIC DRUGS 108 6.5.1 RISING CASES OF EYE-RELATED DISORDERS TO ACCELERATE MARKET GROWTH 108 6.6 NASAL DRUGS 111 6.6.1 ADVANCEMENTS IN NASAL DRUG DELIVERY SYSTEMS AND FAVORABLE REGULATORY POLICIES TO PROPEL MARKET GROWTH 111 6.7 RECTAL DRUGS 114 6.7.1 PERSONALIZED FORMULATIONS AND REGULATORY SUPPORT TO DRIVE GROWTH IN RECTAL COMPOUNDING THERAPIES 114 6.8 OTHER PRODUCTS 117 7 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE 121 7.1 INTRODUCTION 122 7.2 PHARMACEUTICAL DOSAGE ALTERATION 122 7.2.1 TAILORED DOSAGE FORMS TO ENHANCE PATIENT ADHERENCE AND CUSTOMIZATION IN COMPOUNDED MEDICATIONS 122 7.3 PHARMACEUTICAL INGREDIENTS ALTERATION 125 7.3.1 INCREASED NEED FOR CUSTOMIZED PHARMACEUTICAL INGREDIENTS TO ENHANCE PATIENT-CENTRIC COMPOUNDING SOLUTIONS 125 7.4 CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING 128 7.4.1 PERSISTENT GLOBAL DRUG SHORTAGES AND LIMITATIONS OF LARGE-SCALE PHARMACEUTICAL PRODUCTION TO PROPEL ADOPTION 128 8 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION 132 8.1 INTRODUCTION 133 8.2 PAIN MANAGEMENT 133 8.2.1 NEED FOR PERSONALIZED PAIN RELIEF SOLUTIONS FOR CHRONIC AILMENTS TO SUPPORT MARKET 133 8.3 HORMONE REPLACEMENT THERAPIES 136 8.3.1 POPULARITY OF PERSONALIZED HORMONE THERAPIES TO DRIVE STEADY GROWTH IN GLOBAL COMPOUNDING PHARMACY MARKET 136   8.4 DERMAL DISORDERS 139 8.4.1 CUSTOMIZED DERMATOLOGICAL SOLUTIONS TO PROPEL GLOBAL COMPOUNDING PHARMACY MARKET EXPANSION 139 8.5 NUTRITIONAL SUPPLEMENTS 142 8.5.1 PERSONALIZED NUTRACEUTICALS TO OFFER NICHE BUT BETTER GROWTH OPPORTUNITIES IN COMPOUNDING PHARMACIES 142 8.6 OTHER THERAPEUTIC APPLICATIONS 145 9 COMPOUNDING PHARMACY MARKET, BY STERILITY 149 9.1 INTRODUCTION 150 9.2 STERILE 150 9.2.1 RTU/RTA STERILE PREPARATIONS AND OPHTHALMIC PACKS TO DRIVE RAPID GROWTH IN COMPOUNDING PHARMACIES 150 9.3 NON-STERILE 153 9.3.1 503A/MAGISTRAL NON-STERILE PREPARATIONS TO DRIVE GLOBAL VOLUME AND VALUE LEADERSHIP IN COMPOUNDING PHARMACIES 153 10 COMPOUNDING PHARMACY MARKET, BY END USER 157 10.1 INTRODUCTION 158 10.2 ADULTS 158 10.2.1 RISING CHRONIC DISEASE BURDEN AND PERSONALIZED THERAPIES TO AUGMENT ADULT SEGMENT GROWTH 158 10.3 GERIATRIC PATIENTS 161 10.3.1 AGING DEMOGRAPHICS AND DOSE-FORM CUSTOMIZATION TO PROPEL GERIATRIC SEGMENT GROWTH 161 10.4 PEDIATRIC PATIENTS 164 10.4.1 CUSTOMIZED DOSAGE FORMS AND PEDIATRIC-SPECIFIC NEEDS TO DRIVE GROWTH 164 11 COMPOUNDING PHARMACY MARKET, BY REGION 168 11.1 INTRODUCTION 169 11.2 NORTH AMERICA 170 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 171 11.2.2 US 174 11.2.2.1 US to dominate North American compounding pharmacy market during forecast period 174 11.2.3 CANADA 177 11.2.3.1 Personalized treatments, regulatory reinforcement, and supply-gap filling to fuel global compounding pharmacy growth 177   11.3 EUROPE 180 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 180 11.3.2 GERMANY 184 11.3.2.1 Aging demographics, technological advancements, and supportive regulations to drive market 184 11.3.3 UK 186 11.3.3.1 Personalized treatments, chronic disease management, and regulatory support to support market growth 186 11.3.4 FRANCE 189 11.3.4.1 Focus on chronic disease management to fuel growth in French compounding pharmacy market 189 11.3.5 ITALY 191 11.3.5.1 Rising commercial drug development pipeline to spur market growth 191 11.3.6 SPAIN 194 11.3.6.1 Global regulatory advancements and rising R&D activities to drive market 194 11.3.7 REST OF EUROPE 196 11.4 ASIA PACIFIC 199 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 200 11.4.2 CHINA 204 11.4.2.1 Low manufacturing cost and high demand for medicines to favor market growth 204 11.4.3 JAPAN 206 11.4.3.1 Increasing prevalence of chronic diseases and growing geriatric population to fuel demand for customized medications 206 11.4.4 INDIA 209 11.4.4.1 Increasing pharma R&D activities to support market growth 209 11.4.5 AUSTRALIA 211 11.4.5.1 Innovation in clinical practice and regulatory support to accelerate compounding pharmacy growth 211 11.4.6 SOUTH KOREA 213 11.4.6.1 Regulatory innovation and automation to fuel South Korean compounding pharmacy market growth 213 11.4.7 REST OF ASIA PACIFIC 216 11.5 LATIN AMERICA 219 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 219 11.5.2 BRAZIL 222 11.5.2.1 Growing pharmacy & biologics manufacturing sectors and rising R&D sepnding to drive market 222 11.5.3 MEXICO 225 11.5.3.1 Regulatory improvements, high cancer rates, and robust pharmaceutical industry to boost market growth 225 11.5.4 REST OF LATIN AMERICA 227   11.6 MIDDLE EAST & AFRICA 230 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 230 11.6.2 GCC COUNTRIES 234 11.6.2.1 Rising demand for biologics and increasing prevalence of non-communicable diseases to propel market growth 234 11.6.3 REST OF MIDDLE EAST & AFRICA 237 12 COMPETITIVE LANDSCAPE 241 12.1 INTRODUCTION 241 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 241 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023−2025 241 12.3 REVENUE ANALYSIS, 2022–2024 243 12.4 MARKET SHARE ANALYSIS, 2024 244 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 246 12.5.1 STARS 246 12.5.2 EMERGING LEADERS 246 12.5.3 PERVASIVE PLAYERS 246 12.5.4 PARTICIPANTS 246 12.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2024 248 12.5.5.1 Company footprint 248 12.5.5.2 Region footprint 248 12.5.5.3 Product footprint 249 12.5.5.4 Therapeutic application footprint 250 12.5.5.5 Sterility footprint 250 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 251 12.6.1 PROGRESSIVE COMPANIES 251 12.6.2 RESPONSIVE COMPANIES 251 12.6.3 DYNAMIC COMPANIES 251 12.6.4 STARTING BLOCKS 251 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 253 12.6.5.1 Detailed list of key startup/SMEs 253 12.6.5.2 Competitive benchmarking of key startups/SMEs 254 12.7 COMPANY VALUATION & FINANCIAL METRICS 255 12.7.1 FINANCIAL METRICS 255 12.7.2 COMPANY VALUATION 255 12.8 BRAND/PRODUCT COMPARISON 256 12.9 COMPETITIVE SCENARIO 257 12.9.1 PRODUCT LAUNCHES 257 12.9.2 DEALS 258 12.9.3 EXPANSIONS 259   13 COMPANY PROFILES 260 13.1 KEY PLAYERS 260 13.1.1 BAXTER 260 13.1.1.1 Business overview 260 13.1.1.2 Products offered 261 13.1.1.3 Recent developments 262 13.1.1.3.1 Product launches 262 13.1.1.4 MnM view 262 13.1.1.4.1 Key strengths 262 13.1.1.4.2 Strategic choices 262 13.1.1.4.3 Weaknesses & competitive threats 262 13.1.2 EMPOWER PHARMACY 263 13.1.2.1 Business overview 263 13.1.2.2 Products offered 263 13.1.2.3 Recent developments 265 13.1.2.3.1 Expansions 265 13.1.2.4 MnM view 265 13.1.2.4.1 Key strengths 265 13.1.2.4.2 Strategic choices 265 13.1.2.4.3 Weaknesses & competitive threats 265 13.1.3 B. BRAUN SE 266 13.1.3.1 Business overview 266 13.1.3.2 Products offered 267 13.1.3.3 Recent developments 268 13.1.3.3.1 Product launches 268 13.1.3.4 MnM view 268 13.1.3.4.1 Key strengths 268 13.1.3.4.2 Strategic choices 268 13.1.3.4.3 Weaknesses & competitive threats 268 13.1.4 FAGRON 269 13.1.4.1 Business overview 269 13.1.4.2 Products offered 270 13.1.4.3 Recent developments 271 13.1.4.3.1 Deals 271 13.1.4.4 MnM view 271 13.1.4.4.1 Key strengths 271 13.1.4.4.2 Strategic choices 271 13.1.4.4.3 Weaknesses & competitive threats 272   13.1.5 QUVA PHARMA, INC. 273 13.1.5.1 Business overview 273 13.1.5.2 Products offered 273 13.1.5.3 MnM view 274 13.1.5.3.1 Key strengths 274 13.1.5.3.2 Strategic choices 274 13.1.5.3.3 Weaknesses & competitive threats 275 13.1.6 SCA PHARMA 276 13.1.6.1 Business overview 276 13.1.6.2 Products offered 276 13.1.6.3 Recent developments 277 13.1.6.3.1 Deals 277 13.1.7 NEPHRON PHARMACEUTICALS 278 13.1.7.1 Business overview 278 13.1.7.2 Products offered 278 13.1.7.3 Recent developments 279 13.1.7.3.1 Expansions 279 13.1.8 LEITERS HEALTH 280 13.1.8.1 Business overview 280 13.1.8.2 Products offered 280 13.1.8.3 Recent developments 281 13.1.8.3.1 Expansions 281 13.1.9 ICON GROUP 282 13.1.9.1 Business overview 282 13.1.9.2 Products offered 282 13.1.9.3 Recent developments 283 13.1.9.3.1 Deals 283 13.1.10 ROSEWAY LABS 284 13.1.10.1 Business overview 284 13.1.10.2 Products offered 284 13.1.10.3 Recent developments 285 13.1.10.3.1 Other developments 285 13.1.11 ITH PHARMA 286 13.1.11.1 Business overview 286 13.1.11.2 Products offered 286 13.1.12 PENCOL COMPOUNDING PHARMACY 287 13.1.12.1 Business overview 287 13.1.12.2 Products offered 287 13.1.13 FORMUL8 288 13.1.13.1 Business overview 288 13.1.13.2 Products offered 288   13.1.14 AURORA COMPOUNDING PHARMACY 289 13.1.14.1 Business overview 289 13.1.14.2 Products offered 289 13.2 OTHER PLAYERS 290 13.2.1 CUSTOM MED APOTHECARY 290 13.2.2 INSTITUTIONAL PHARMACY SOLUTIONS 291 13.2.3 FUSION APOTHECARY 291 13.2.4 INNOVATION COMPOUNDING PHARMACY 292 13.2.5 RX3 COMPOUNDING PHARMACY 292 13.2.6 DOUGHERTY’S PHARMACY, INC. 293 13.2.7 LORRAINE’S PHARMACY 293 13.2.8 WELLS PHARMA 294 13.2.9 OLYMPIA PHARMACY 294 13.2.10 FRESH THERAPEUTICS 295 13.2.11 MEDIOS AG 296 14 APPENDIX 297 14.1 DISCUSSION GUIDE 297 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 301 14.3 CUSTOMIZATION OPTIONS 303 14.4 RELATED REPORTS 303 14.5 AUTHOR DETAILS 304
圖表清單 List of Tables & Figures
TABLE 1 COMPOUNDING PHARMACY MARKET: INCLUSIONS & EXCLUSIONS 33 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 44 TABLE 3 COMPOUNDING PHARMACY MARKET: RISK ANALYSIS 47 TABLE 4 COMPOUNDING PHARMACY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 61 TABLE 5 COMPOUNDING PHARMACY MARKET: PORTER’S FIVE FORCES 67 TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPOUNDING PHARMACY PRODUCTS (%) 70 TABLE 7 KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER 71 TABLE 8 HEALTH EXPENDITURE AND FINANCING, 2015–2024 (% OF GDP) 72 TABLE 9 US: CANCER INCIDENCE, BY STATE (2024) 74 TABLE 10 COMPOUNDING PHARMACY MARKET: ROLE IN ECOSYSTEM 78 TABLE 11 INDICATIVE PRICING ANALYSIS COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2024 79 TABLE 12 INDICATIVE PRICING ANAYLSIS OF COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2024 80 TABLE 13 COMPOUNDING PHARMACY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 80 TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 18 COUNTRY-WISE REGULATORY SCENARIO FOR COMPOUNDING PHARMACIES 89 TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 93 TABLE 20 COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 99 TABLE 21 COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 22 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 23 EUROPE: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 24 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 25 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 26 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 27 COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 28 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 29 EUROPE: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 30 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 31 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 32 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 33 COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 34 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 35 EUROPE: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 36 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 37 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 38 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 39 COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 40 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 41 EUROPE: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 42 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 43 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 44 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 45 COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 46 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 47 EUROPE: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 48 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 49 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 50 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 51 COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 52 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 53 EUROPE: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 54 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 55 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 56 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 57 COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 58 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 59 EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 60 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 61 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 62 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 63 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 122 TABLE 64 COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 65 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 66 EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 67 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 68 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 69 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 70 COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 71 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 72 EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 73 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 74 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 75 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 76 COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 77 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 78 EUROPE: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 79 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 80 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 81 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 82 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 133 TABLE 83 COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 84 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 85 EUROPE: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 86 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 87 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 88 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 89 COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 90 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 91 EUROPE: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 92 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 93 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 94 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 95 COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 96 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 97 EUROPE: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 98 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 99 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 100 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 101 COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 102 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 103 EUROPE: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 104 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 105 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 106 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 107 COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 108 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 109 EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 110 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 111 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 112 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 148 TABLE 113 COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 150 TABLE 114 STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 115 NORTH AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 116 EUROPE: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 117 ASIA PACIFIC: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 118 LATIN AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 119 MIDDLE EAST & AFRICA: STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 120 NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 121 NORTH AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 122 EUROPE: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 123 ASIA PACIFIC: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 124 LATIN AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 125 MIDDLE EAST & AFRICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 126 COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 158 TABLE 127 COMPOUNDING PHARMACY MARKET FOR ADULTS, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 128 NORTH AMERICA: COMPOUNDING PHARMACY MARKET ADULTS, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 129 EUROPE: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 130 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 131 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 132 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 133 COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 134 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 135 EUROPE: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 136 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 137 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 138 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 139 COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 140 NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 141 EUROPE: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 142 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 143 LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 144 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION) 167 TABLE 145 COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 146 NORTH AMERICA: KEY MACROINDICATORS 171 TABLE 147 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 148 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 172 TABLE 149 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 173 TABLE 150 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 173 TABLE 151 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 174 TABLE 152 NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 174 TABLE 153 US: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 175 TABLE 154 US: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 175 TABLE 155 US: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 176 TABLE 156 US: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 176 TABLE 157 US: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 176 TABLE 158 CANADA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 177 TABLE 159 CANADA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 178 TABLE 160 CANADA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 178 TABLE 161 CANADA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 179 TABLE 162 CANADA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 179 TABLE 163 EUROPE: KEY MACROINDICATORS 181 TABLE 164 EUROPE: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 165 EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 182 TABLE 166 EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 182 TABLE 167 EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 183 TABLE 168 EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 183 TABLE 169 EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 183 TABLE 170 GERMANY: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 184 TABLE 171 GERMANY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 185 TABLE 172 GERMANY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 185 TABLE 173 GERMANY: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 186 TABLE 174 GERMANY: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 186 TABLE 175 UK: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 187 TABLE 176 UK: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 187 TABLE 177 UK: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 188 TABLE 178 UK: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 188 TABLE 179 UK: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 188 TABLE 180 FRANCE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 189 TABLE 181 FRANCE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 190 TABLE 182 FRANCE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 190 TABLE 183 FRANCE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 191 TABLE 184 FRANCE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 191 TABLE 185 ITALY: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 192 TABLE 186 ITALY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 192 TABLE 187 ITALY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 193 TABLE 188 ITALY: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 193 TABLE 189 ITALY: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 193 TABLE 190 SPAIN: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 194 TABLE 191 SPAIN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 195 TABLE 192 SPAIN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 195 TABLE 193 SPAIN: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 196 TABLE 194 SPAIN: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 196 TABLE 195 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 197 TABLE 196 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 197 TABLE 197 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 198 TABLE 198 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 198 TABLE 199 REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 199 TABLE 200 ASIA PACIFIC: KEY MACROINDICATORS 201 TABLE 201 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 202 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 202 TABLE 203 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 202 TABLE 204 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 203 TABLE 205 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 203 TABLE 206 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 204 TABLE 207 CHINA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 204 TABLE 208 CHINA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 205 TABLE 209 CHINA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 205 TABLE 210 CHINA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 206 TABLE 211 CHINA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 212 JAPAN: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 207 TABLE 213 JAPAN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 207 TABLE 214 JAPAN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 208 TABLE 215 JAPAN: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 208 TABLE 216 JAPAN: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 208 TABLE 217 INDIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 209 TABLE 218 INDIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 209 TABLE 219 INDIA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 210 TABLE 220 INDIA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 210 TABLE 221 INDIA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 210 TABLE 222 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 211 TABLE 223 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 212 TABLE 224 AUSTRALIA : COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 212 TABLE 225 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 213 TABLE 226 AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 213 TABLE 227 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 214 TABLE 228 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 214 TABLE 229 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 215 TABLE 230 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 215 TABLE 231 SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 216 TABLE 232 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 216 TABLE 233 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 217 TABLE 234 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 217 TABLE 235 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 218 TABLE 236 REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 218 TABLE 237 LATIN AMERICA: KEY MACROINDICATORS 219 TABLE 238 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 239 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 220 TABLE 240 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 221 TABLE 241 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 221 TABLE 242 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 222 TABLE 243 LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 222 TABLE 244 BRAZIL: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 223 TABLE 245 BRAZIL: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 223 TABLE 246 BRAZIL: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 224 TABLE 247 BRAZIL: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 224 TABLE 248 BRAZIL: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 224 TABLE 249 MEXICO: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 225 TABLE 250 MEXICO: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 226 TABLE 251 MEXICO: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 226 TABLE 252 MEXICO: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 227 TABLE 253 MEXICO: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 227 TABLE 254 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 228 TABLE 255 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 228 TABLE 256 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 229 TABLE 257 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 229 TABLE 258 REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 259 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 231 TABLE 260 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION) 231 TABLE 261 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 232 TABLE 262 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 232 TABLE 263 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 233 TABLE 264 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 233 TABLE 265 MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 234 TABLE 266 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 235 TABLE 267 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 235 TABLE 268 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 236 TABLE 269 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 236 TABLE 270 GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 237 TABLE 271 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 238 TABLE 272 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION) 238 TABLE 273 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION) 239 TABLE 274 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION) 239 TABLE 275 REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION) 240 TABLE 276 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023–2025 241 TABLE 277 COMPOUNDING PHARMACY MARKET: DEGREE OF COMPETITION 245 TABLE 278 COMPOUNDING PHARMACY MARKET: REGION FOOTPRINT 248 TABLE 279 COMPOUNDING PHARMACY MARKET: PRODUCT FOOTPRINT 249 TABLE 280 COMPOUNDING PHARMACY MARKET: THERAPEUTIC APPLICATION FOOTPRINT 250 TABLE 281 COMPOUNDING PHARMACY MARKET: STERILITY FOOTPRINT 250 TABLE 282 COMPOUNDING PHARMACY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 253 TABLE 283 COMPOUNDING PHARMACY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT, THERAPEUTIC APPLICATION, AND REGION, 2024 254 TABLE 284 COMPOUNDING PHARMACY MARKET: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025 257 TABLE 285 COMPOUNDING PHARMACY MARKET: DEALS, JANUARY 2022–OCTOBER 2025 258 TABLE 286 COMPOUNDING PHARMACY MARKET: EXPANSIONS, JANUARY 2022–OCTOBER 2025 259   TABLE 287 BAXTER: COMPANY OVERVIEW 260 TABLE 288 BAXTER: PRODUCTS OFFERED 261 TABLE 289 BAXTER: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025 262 TABLE 290 EMPOWER PHARMACY: COMPANY OVERVIEW 263 TABLE 291 EMPOWER PHARMACY: PRODUCTS OFFERED 263 TABLE 292 EMPOWER PHARMACY: EXPANSIONS, JANUARY 2022–OCTOBER 2025 265 TABLE 293 B. BRAUN SE: COMPANY OVERVIEW 266 TABLE 294 B. BRAUN SE: PRODUCTS OFFERED 267 TABLE 295 B. BRAUN SE: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025 268 TABLE 296 FAGRON: COMPANY OVERVIEW 269 TABLE 297 FAGRON: PRODUCTS OFFERED 270 TABLE 298 FAGRON: DEALS, JANUARY 2022–OCTOBER 2025 271 TABLE 299 QUVA PHARMA, INC.: COMPANY OVERVIEW 273 TABLE 300 QUVA PHARMA, INC.: PRODUCTS OFFERED 273 TABLE 301 SCA PHARMA: COMPANY OVERVIEW 276 TABLE 302 SCA PHARMA: PRODUCTS OFFERED 276 TABLE 303 SCA PHARMA: DEALS, JANUARY 2022–OCTOBER 2025 277 TABLE 304 NEPHRON PHARMACEUTICALS: COMPANY OVERVIEW 278 TABLE 305 NEPHRON PHARMACEUTICALS: PRODUCTS OFFERED 278 TABLE 306 NEPHRON PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–OCTOBER 2025 279 TABLE 307 LEITERS HEALTH: COMPANY OVERVIEW 280 TABLE 308 LEITERS HEALTH: PRODUCTS OFFERED 280 TABLE 309 LEITERS HEALTH: EXPANSIONS, JANUARY 2022–OCTOBER 2025 281 TABLE 310 ICON GROUP: COMPANY OVERVIEW 282 TABLE 311 ICON GROUP: PRODUCTS OFFERED 282 TABLE 312 ICON GROUP: DEALS, JANUARY 2022–OCTOBER 2025 283 TABLE 313 ROSEWAY LABS: COMPANY OVERVIEW 284 TABLE 314 ROSEWAY LABS: PRODUCTS OFFERED 284 TABLE 315 ROSEWAY LABS: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025 285 TABLE 316 ITH PHARMA: COMPANY OVERVIEW 286 TABLE 317 ITH PHARMA: PRODUCTS OFFERED 286 TABLE 318 PENCOL COMPOUNDING PHARMACY: COMPANY OVERVIEW 287 TABLE 319 PENCOL COMPOUNDING PHARMACY: PRODUCTS OFFERED 287 TABLE 320 FORMUL8: COMPANY OVERVIEW 288 TABLE 321 FORMUL8: PRODUCTS OFFERED 288 TABLE 322 AURORA COMPOUNDING PHARMACY: COMPANY OVERVIEW 289 TABLE 323 AURORA COMPOUNDING PHARMACY: PRODUCTS OFFERED 289 TABLE 324 CUSTOM MED APOTHECARY: COMPANY OVERVIEW 290 TABLE 325 INSTITUTIONAL PHARMACY SOLUTIONS: COMPANY OVERVIEW 291 TABLE 326 FUSION APOTHECARY: COMPANY OVERVIEW 291   TABLE 327 INNOVATION COMPOUNDING PHARMACY: COMPANY OVERVIEW 292 TABLE 328 RX3 COMPOUNDING PHARMACY: COMPANY OVERVIEW 292 TABLE 329 DOUGHERTY’S PHARMACY, INC.: COMPANY OVERVIEW 293 TABLE 330 LORRAINE’S PHARMACY: COMPANY OVERVIEW 293 TABLE 331 WELLS PHARMA: COMPANY OVERVIEW 294 TABLE 332 OLYMPIA PHARMACY: COMPANY OVERVIEW 294 TABLE 333 FRESH THERAPEUTICS: COMPANY OVERVIEW 295 TABLE 334 MEDIOS AG: COMPANY OVERVIEW 296 FIGURE 1 COMPOUNDING PHARMACY MARKET SEGMENTATION & REGIONAL SCOPE 32 FIGURE 2 COMPOUNDING PHARMACY MARKET: YEARS CONSIDERED 33 FIGURE 3 COMPOUNDING PHARMACY MARKET: RESEARCH DESIGN 35 FIGURE 4 COMPOUNDING PHARMACY MARKET: KEY DATA FROM SECONDARY SOURCES 37 FIGURE 5 COMPOUNDING PHARMACY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 38 FIGURE 6 COMPOUNDING PHARMACY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 39 FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024) 40 FIGURE 8 REVENUE SHARE ANALYSIS OF BAXTER (2024) 40 FIGURE 9 COMPOUNDING PHARMACY MARKET SIZE VALIDATION FROM PRIMARY SOURCES 41 FIGURE 10 COMPOUNDING PHARMACY MARKET: TOP-DOWN APPROACH 42 FIGURE 11 COMPOUNDING PHARMACY MARKET: CAGR PROJECTIONS 44 FIGURE 12 COMPOUNDING PHARMACY MARKET: DATA TRIANGULATION 46 FIGURE 13 COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 50 FIGURE 14 COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2025 VS. 2030 (USD MILLION) 51 FIGURE 15 COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD MILLION) 51 FIGURE 16 COMPOUNDING PHARMACY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 52 FIGURE 17 REGIONAL SNAPSHOT OF COMPOUNDING PHARMACY MARKET 53 FIGURE 18 RISING TREND OF PERSONALISED MEDICINES TO PROPEL MARKET GROWTH 54 FIGURE 19 US AND 0RAL DRUGS SEGMENT TO COMMAND LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025 55 FIGURE 20 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 56 FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD 57 FIGURE 22 COMPOUNDING PHARMACY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60 FIGURE 23 TOTAL PRESCRIPTION DRUG SALES, 2023–2030 (USD BILLION) 63 FIGURE 24 COMPOUNDING PHARMACY MARKET: PORTER’S FIVE FORCES ANALYSIS 67 FIGURE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF KEY COMPOUNDING PHARMACY PRODUCTS 69 FIGURE 26 KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER 71 FIGURE 27 GLOBAL PHARMACEUTICAL R&D EXPENDITURE, 2023–2030 (USD BILLION) 75 FIGURE 28 COMPOUNDING PHARMACY MARKET: VALUE CHAIN ANALYSIS 76 FIGURE 29 COMPOUNDING PHARMACY MARKET: ECOSYSTEM MAP 77 FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN COMPOUNDING PHARMACY MARKET 82 FIGURE 31 INVESTMENT AND NUMBER OF DEALS IN COMPOUNDING PHARMACY MARKET, 2023–2025 (USD MILLION) 82 FIGURE 32 COMPOUNDING PHARMACY MARKET: IMPACT OF AI/GEN AI 85 FIGURE 33 NORTH AMERICA: COMPOUNDING PHARMACY MARKET SNAPSHOT 170 FIGURE 34 ASIA PACIFIC: COMPOUNDING PHARMACY MARKET SNAPSHOT 200 FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2022–2024 (USD MILLION) 243 FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET (2024) 244 FIGURE 37 COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 247 FIGURE 38 COMPOUNDING PHARMACY MARKET: COMPANY FOOTPRINT 248 FIGURE 39 COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 252 FIGURE 40 EV/EBITDA OF KEY VENDORS 255 FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 255 FIGURE 42 COMPOUNDING PHARMACY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 256 FIGURE 43 BAXTER: COMPANY SNAPSHOT (2024) 261 FIGURE 44 B. BRAUN SE: COMPANY SNAPSHOT (2024) 267 FIGURE 45 FAGRON: COMPANY SNAPSHOT (2024) 270

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們